CD274 and melanoma: To examine the effects of PDI-1 treatment on tumor growth, groups of C57BL/6 mice (B16-F10 syngeneic) were subcutaneously injected with hPD-L1-B16-F10 melanoma cells (Figure 4) or groups of DBA/2 mice (KLN205 syngeneic) were injected subcutaneously with hPD-L1-KLN205 cells (Figure 5), and the mice were injected intraperitoneally with the vehicle, 4 mg/kg PDI-1, or 8 mg/kg PDI-1 once daily for either 29 days (C57BL/6) or 33 days (DBA/2).